Zynerba Pharmaceuticals
Market Cap
US$108.8m
Last Updated
2020/10/25 01:15 UTC
Data Sources
Company Financials +
Executive Summary
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and fair value.
Share Price & News
How has Zynerba Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZYNE has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-3.4%
ZYNE
-1.1%
US Pharmaceuticals
-0.4%
US Market
1 Year Return
-54.4%
ZYNE
10.8%
US Pharmaceuticals
18.3%
US Market
Return vs Industry: ZYNE underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: ZYNE underperformed the US Market which returned 18.3% over the past year.
Shareholder returns
| ZYNE | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.4% | -1.1% | -0.4% |
| 30 Day | 13.4% | 1.4% | 8.0% |
| 90 Day | -0.3% | 0.7% | 9.4% |
| 1 Year | -54.4%-54.4% | 13.7%10.8% | 21.0%18.3% |
| 3 Year | -62.0%-62.0% | 25.5%16.2% | 42.1%32.7% |
| 5 Year | -70.5%-70.5% | 39.7%23.3% | 85.6%64.7% |
Price Volatility Vs. Market
How volatile is Zynerba Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
What We Learned About Zynerba Pharmaceuticals' (NASDAQ:ZYNE) CEO Compensation2 months ago | Simply Wall St
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?3 months ago | Simply Wall St
How Much Is Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Paying Its CEO?Valuation
Is Zynerba Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZYNE ($3.72) is trading below our estimate of fair value ($260.24)
Significantly Below Fair Value: ZYNE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZYNE is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ZYNE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZYNE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZYNE is good value based on its PB Ratio (1.5x) compared to the US Pharmaceuticals industry average (3x).
Next Steps
Future Growth
How is Zynerba Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
65.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZYNE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZYNE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZYNE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZYNE's revenue (75.1% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ZYNE's revenue (75.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZYNE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Zynerba Pharmaceuticals performed over the past 5 years?
-21.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZYNE is currently unprofitable.
Growing Profit Margin: ZYNE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZYNE is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
Accelerating Growth: Unable to compare ZYNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZYNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.6%).
Return on Equity
High ROE: ZYNE has a negative Return on Equity (-60.91%), as it is currently unprofitable.
Next Steps
Financial Health
How is Zynerba Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ZYNE's short term assets ($85.3M) exceed its short term liabilities ($13.1M).
Long Term Liabilities: ZYNE has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ZYNE is debt free.
Reducing Debt: ZYNE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZYNE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZYNE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Zynerba Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZYNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZYNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZYNE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZYNE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZYNE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.0yrs
Average management tenure
CEO
Armando Anido (62 yo)
6yrs
Tenure
US$1,369,571
Compensation
Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. He has m ...
CEO Compensation Analysis
Compensation vs Market: Armando's total compensation ($USD1.37M) is above average for companies of similar size in the US market ($USD579.76K).
Compensation vs Earnings: Armando's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 6yrs | US$1.37m | 1.34% $ 1.5m | |
| President | 6yrs | US$1.04m | 0.64% $ 692.5k | |
| CFO, VP of Corporate Development & Treasurer | 4.08yrs | US$824.11k | 0.071% $ 77.1k | |
| VP of Investor Relations & Corporate Communications | 3.25yrs | no data | no data | |
| Secretary | 6yrs | US$791.52k | no data | |
| Chief Medical Officer | 1.17yrs | no data | no data |
5.0yrs
Average Tenure
62yo
Average Age
Experienced Management: ZYNE's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 6yrs | US$1.37m | 1.34% $ 1.5m | |
| Independent Director | 5.17yrs | US$183.85k | no data | |
| Independent Director | 5.17yrs | US$182.47k | no data | |
| Lead Independent Director | 4.92yrs | US$202.10k | no data | |
| Independent Director | 5.17yrs | US$190.60k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Independent Director | 1.67yrs | US$295.03k | no data |
5.1yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ZYNE's board of directors are considered experienced (5.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.1%.
Top Shareholders
Company Information
Zynerba Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zynerba Pharmaceuticals, Inc.
- Ticker: ZYNE
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$108.785m
- Shares outstanding: 29.24m
- Website: https://www.zynerba.com
Number of Employees
Location
- Zynerba Pharmaceuticals, Inc.
- 80 West Lancaster Avenue
- Suite 300
- Devon
- Pennsylvania
- 19333
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ZYNE | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Aug 2015 |
| 6ZY | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Aug 2015 |
| 0M40 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Aug 2015 |
Biography
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neur ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/25 01:15 |
| End of Day Share Price | 2020/10/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.